menu search

TCRR / Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDAQ: ADAP ). Meanwhile, Adaptimmune is falling more than 15%. Read More
Posted: Mar 6 2023, 10:45
Author Name: InvestorPlace
Views: 102849

TCRR News  

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

By InvestorPlace
March 6, 2023

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDA more_horizontal

TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path

By Seeking Alpha
February 15, 2023

TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path

Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gav more_horizontal

TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

By GlobeNewsWire
November 23, 2022

TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of no more_horizontal


Search within

Pages Search Results: